While IL-6 blockade therapy is highly effective in a subset of RA patients, IL-1 blockade with anakinra, although an FDA-approved therapy for RA that is effective at suppressing tissue degradation, appears to have limited efficacy in suppressing inflammatory symptoms. Here, IL6 is linked to rheumatoid arthritis.